ISBN: 978-83-60043-10-3 - eurobic9

Eurobic9, 2-6 September, 2008, Wrocław, Poland
P70. Compatibility Study Between Sulfasalazin and Sucralfat in vivo Using
HPLC
B. Grimling, J. Meler, J. Pluta
Dispensing Pharmacy of Wroclaw Medical University, Szewska 38/39, 54-139, Wrocław, Poland,
The need of parallel treatment of two or more affections and the resulting necessity of using a few drugs from
different pharmacological groups creates the danger of interactions witch may decrease effectiveness of the
applied therapy. Sucralfat is a complex salt of saccharose octosulfate with apparent adsorption qualities. The
proximity of a weak acid such as sulfasalazin makes it possible to assume an interaction based on adsorption of
this medicine on the surface of sucralfat polyanions. In the first study, four healthy male volunteers received a
single, oral 500-mg dose of salicylazosulfapyridine three times a day. In the second study, six patients receive
oral 500 mg oral dose salicylazosulphapirydine three times a day and Sucralfate 1g one once a day.
In study 1, urine was collected just before dosing and in 24-hour blocks for at least 1 day after administration of
Sulfasalazin. In study 2, all urine collected for 24 hours after Sulfasalazin and Sucralfate[1]. The concentration
of sulfasalazin (salicylazosulfapyridine, SSA) and its metabolites: 5-aminosalicylic acid (5-ASA), acetyl-5 -
aminosalicylic acid (Ac-5-ASA), sulphapyridine (SP), acetylsulphapyridine Ac-SP) was determined by a
reverse-phase HPLC (Gilson) using Zorbax ODS C-18 (250mm×4.6mm, 5µm) column. The mobile phase
consisted of 25% methanol in 5mM phosphate buffer (pH 6.0) containing 0.5mM tetrabutylammonium chloride,
which was filtered through 0.45 µm membrane filter before use. Samples (20 µl) were injected and eluted with
the mobile phase at a flow rate of 2, 0 ml/min. The eluate was monitored at 257nm at sensitivity of AUFS 0.001.
The retention times of 5-ASA was, SP and SP was 8, 49, SAS was 12, 01, Ac-SP was 15.03 and Ac-5-ASA was
15.75 min, respectively.The observed differences of concentrations in dependence from applied therapy were
extremely essential statistic, on level of significance and = 0, 001(the p < 0, 001). This analysis, that the fall of
concentration of higher described metabolite in urine during applying the therapy associated it is not the random
phenomenon treat with rule. It the analysis of introduced data was affirmed was, that presence sucralfat in
associated from sulfasalasine therapy reduces concentration sulfasalasine as well as her two metabolite in studied
patients' urine[2].
References:
[1]. Jung, Y.J., Kim, H.H., Kong, H.S., Kim, Y.M., 2003. Synthesis and properties of 5-aminosalicyl-taurine as a
colon-specific prodrug of 5-aminosalicylic acid. Arch. Pharm. Res. 26, 264-269.
[2]. Schroder, H., Campbell, D.E., 1972. Absorption, metabolism, and excretion of salicylazosulfapyridine in
man. Clin. Pharmacol. Ther. 13, 539-551.
_____________________________________________________________________
189